Company Profile
Terns Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Terns Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Terns Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Terns Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Terns Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
TERN is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Terns Pharmaceuticals's catalysts are TERN-601 in obesity and TERN-701 in CML, the two programs that most directly determine whether the company has a real differentiated future. The market will care about whether either asset can keep the story moving.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Terns Announces Proposed Public Offering
Source: Terns Pharmaceuticals
- 02
Terns Announces Pricing of Upsized $650 Million Public Offering
Source: Terns Pharmaceuticals
- 03
- 04
- 05
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Source: Terns Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.